News
Concerns over international reference pricing in the EU
2011-11-28 An independent report commissioned by the European Parliament’s committee for Environment, Public Health and Food Safety (ENVI) has highlighted some problems with ac...
Read more
How successful is the reference pricing system in Belgium
2011-11-25 The main aim of a reference pricing system (RPS) is to provide generic medicines at the lowest cost to the state and individuals. This article explains how RPSs work...
Read more
Scottish government considering generic substitution
2011-11-24 A Scottish politician revealed on 17 November 2010 that the Scottish government is currently considering whether to introduce generic substitution as part of ongoing...
Read more
Problematic patent settlements in EU on the decrease
2011-11-22 The European Commission’s (EC) second monitoring exercise of patent settlements in the pharmaceutical sector has shown a continuing decline of potentially problemati...
Read more
Biosimilar substitution in the EU
2011-11-18 Although many things—including regulations for licensing of biosimilars—are harmonised within the EU, the attitude towards biosimilars and their substitution within...
Read more
Boehringer Ingelheim joins other Big Pharma going into biosimilars
2011-11-17 Big Pharma is once again taking a major interest in biosimilars. The latest big pharmaceutical player to show an interest is biopharmaceutical specialist Boehringer...
Read more
EC to investigate patent settlements again
2011-11-16 The European Commission (EC) has once again requested information from pharmaceutical companies regarding patent settlement agreements concluded in the European Econ...
Read more
Medicines pricing policies in Europe: a review
2011-11-15 The OECD countries spent 4.6% more per capita per year on pharmaceuticals from 1995 to 2005 although the annual average economic growth was only 2.2% during the same...
Read more
EMA biosimilar regulation should include complex biologicals
2011-10-17 The EMA’s comprehensive biosimilar regulatory pathway, which includes the need for new clinical trials and comparability studies that demonstrate quality, efficacy,...
Read more
EMA comparability studies limiting biosimilar success
2011-10-14 The EMA’s comprehensive biosimilar regulatory pathway, which includes the need for new clinical trials and comparability studies that demonstrate quality, efficacy,...
Read more
Actavis launches generic olanzapine in 11 European markets
2011-10-13 Eli Lilly is facing yet more pressure as generics makers queue up to produce copies of its blockbuster antipsychotic drug Zyprexa (olanzapine). On 30 September 2011,...
Read more
Hospira looks to biosimilars and increased use of generics for growth
2011-10-12 Injectable generics leader, Hospira, announced on 7 September 2011 at its investor day, that it will look to biosimilars and international expansion for future growt...
Read more
Last update: 2008-09-06 | 
Go Back | 
Print View